Archive news

• 16 March 2021 – Stasera Italia, the Italian way to the COVID-19 vaccine

  16 March 2021 – Stasera Italia, the Italian way to the COVID-19 vaccine COVID-eVax is the second Italian vaccine to enter clinical trials and the first of its kind to reach…

• 14 March 2021 – TGR Officina Italia, Italy is going to produce COVID-19 vaccines

  14 March 2021 – TGR Officina Italia, Italy is going to produce COVID-19 vaccines Italy can make a fundamental contribution to the fight against the pandemic by participating in the European…

• 9 March 2021 – Agorà, a new vaccine entirely made in Italy

  9 March 2021 – Agorà, a new vaccine entirely made in Italy Emanuele Marra – Director of Infectious Disease Area – and Giuseppe Roscilli – Director of Antibody Development Area –…

• 4 March 2021 – The first volunteer tested Takis vaccine COVID-eVax

  4 March 2021 – The first volunteer tested Takis vaccine COVID-eVax Luca Rivolti, 21, is the first volunteer who tested the vaccine against COVID-19 developed by Takis and Rottapharm biotech. The…

• 1 March 2021 - The phase I/II Clinical Study of the first European DNA Vaccine against Covid-19 has started today…

  Download PDF Italian Version Download PDF March 1, 2021 - The first healthy volunteers received the initial dose of the DNA vaccine against COVID-19 (COVID-eVax) designed by Takis and developed in collaboration…

• 24 February 2021 – Takis ranked first in Regione Lazio

  24 February 2021 – Takis ranked first in Regione Lazio Takis ranked first in the call “Emergenza Coronavirus ed Oltre” in the event “L’innovazione oltre l’emergenza” organized by Regione Lazio in…

• 3 February 2021 - Takis and Rottapharm Biotech announce the authorization of the clinical trial by the Italian Medicines Agency…

  Download PDF Italian Version Download PDF Takis and Rottapharm Biotech announce the authorization of the clinical trial by the Italian Medicines Agency (AIFA) of COVID-eVax, the vaccine against COVID-19 designed by Takis…

• 18 December 2020 – Takis added to the EU Malaria Fund portfolio

  Takis has been added to the European Malaria Fund portfolio. The EU Malaria Fund is a public-private partnership between the European Union, international organizations, corporations and organized civil society, providing a…

• Applied DNA and Evvivax Initiate Phase I of Clinical Trial to Evaluate LinearDNA™ COVID-19

  STONY BROOK, N.Y. and ROME, ITALY – March 2, 2021 - Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, and its…

• 17 December 2020 – Our opinion on Sars-Cov-2 vaccines on SIMeF journal

  Luigi Aurisicchio, CEO of Takis, and Lucio Rovati, CEO of Rottapharm biotech, interviewed on the journal of SIMeF – Società Italiana di Medicina Farmaceutica.   They talked about the contribution of…

• 11 December 2020 – COVID-eVax, clinical trials are about to begin

  In January, the clinical trial of our DNA vaccine for Covid-19 - 100% made in Italy - will begin at the research center of the San Gerardo Hospital in Monza…

• 3 December 2020 – Takis working on vaccines against SARS-Cov-2 variants

  WIth the first generation of vaccine against COVID-19 being investigated in clinical trials, vaccines able to fight the new emerging variants of the SARS-CoV-2 virus will be the next goal…

• 14 November 2020 – Takis COVID-eVax within covidX European platform!

  Our vaccine COVID-eVax has been described within Covidx initiative, together with other ongoing European projects aimed at fighting SARS-Cov-2 pandemics. Covidx platform provides the public with up-to-date and accurate information…

• 21 September 2020 - Takis for the project TraZimab against invasive aspergillosis

  Takis collaborates in the “TraZimab” project coordinated by Menarini Biotech and financed by Lazio Innova. The project put together three important local organizations - Menarini Biotech, Takis and OPBG (Bambin…

• 18 luglio 2020 - Takis e Fondazione Melanoma insieme verso il vaccino contro COVID-19

  Napoli e Roma, 18 luglio 2020 – Takis e Fondazione Melanoma annunciano una collaborazione scientifica finalizzata alla sperimentazione clinica del vaccino contro COVID-19 in autunno, denominato COVID-eVax. In particolare, Fondazione…

• 25 June 2020 – Takis live on Tagadà - La7

  The CEO of Takis Luigi Aurisicchio, interviewed by Tagadà – La7, gave a brief demonstration on how our COVID-19 vaccine will be administered to patients by DNA-electroporation technology. In addition, he…

• 9 June 2020 - Takis publishes a letter exploring benefits and drawbacks of genetic vaccines against Sars-Cov-2

  In this letter to the editor, we summarized advantages and drawbacks of current genetic vaccination approaches against COVID-19. Despite some intrinsic limitations, DNA-based vaccines are an ideal vaccination platform for infectious…

• 04 Giu 2020 – Una donazione di Euler Hermes a supporto della ricerca sul vaccino anti-COVID-19 di Takis

  Luigi Aurisicchio, CEO e Founder di Takis racconta: «L’incontro con Euler Hermes è stato importantissimo perché ci ha dato un grande contributo che ci aiuterà a caratterizzare il tipo di…

• 3 June 2020 – A brief commentary about Spike protein as an optimal immunological target for vaccines

  In this commentary, we outline the strategies and targets currently adopted in developing a vaccine against SARS-CoV-2. Based on previous evidence and experience with SARS and MERS, the primary focus…

• 3 Jun 2020 – Covid-19: accordo tra Takis e Rottapharm Biotech sullo sviluppo del vaccino

  Aurisicchio Ad Takis: “Un’opportunità sinergica e nuovi stimoli”. Lucio Rovati, Presidente e Direttore Scientifico di Rottapharm Biotech; “non solo i capitali per la prima fase di sperimentazione, ma soprattutto il…

• 22 May 2020 – Takis on “Il Fatto Quotidiano”: inside the Italian labs working on the Covid-19 vaccine

  Takis has been mentioned in the video reportage on “Il Fatto Quotidiano” dedicated to the three Italian companies based near Rome that are working on the development of a Covid-19…

• 18 May 2020 – Takis on Repubblica TV special “Meet the future”

  Luigi Aurisicchio, CEO of Takis, has been a host on the special “Meet the future” about biotech and coronavirus, organized by Repubblica TV in collaboration with Assobiotec. Scientists, entrepreneurs and politicians…

• 9 May 2020 – Takis announces Neomatrix, a company fully dedicated to personalized cancer vaccines

  NEOMATRIX is a individualised therapeutic cancer vaccine against tumour specific antigens, called neoantigens, arising from somatic gene mutations in malignant cells during neoplastic transformation. The tailored vaccine is intended for…

• Takis vaccines neutralize SARS-CoV-2

  After inducing antibodies in animal models, Takis vaccines have proven effective in neutralizing the SARS-CoV-2 virus, thanks to the collaboration with the Spallanzani Institute in Rome "The results obtained to date…

• 27 April 2020 – Speaking about Covid-19 vaccine development on Radio Cusano Campus

  On Radio Cusano Campus – Genetica Oggi, our CEO / CSO Luigi Aurisicchio answered key questions on the clinical development of the Covid-19 vaccine: when it is ready, who will…

• 21 April 2020 – Takis’ race to develop a Covid-19 vaccine on Forbes

  Forbes dedicated a fascinating article about Takis and our race to develop a vaccine against the new Coronavirus Sars-Cov-2. Covid-19 is an opportunity for us to learn: this is the first…

• 10-april-2020 - Takis candidate vaccines against Covid-19 induce a strong antibody response

  We are proud to announce that the results of our first study on animal models are extremely positive. After a single dose, our five candidate DNA-based vaccines were able to…

• 31 March 2020 – Have a look at Takis labs on Sky-TG24!

  Sky-TG24 has dedicated a television report about Takis and our vaccine against Covid-19. Luigi Aurisicchio, CEO/CSO of Takis and Evvivax, and Emanuele Marra, Director of Infectious Diseases Area, have shown…

• 31 March 2020 – Takis on the Italian TV program “Otto e mezzo”

  Luigi Aurisicchio, CEO/CSO of Takis and Evvivax, in Skype connection on the Italian TV program “Otto e mezzo” conducted by Lilli Gruber. They talked about the economic impact of Covid-19 and…

• 25 March 2020 – Takis on the Italian TV program “Presa Diretta”

  Have a look at our young and talented researchers while they are working on the development of Covid-19 vaccine in our laboratories based in Castel Romano! Luigi Aurisicchio, CEO/CSO of Takis…

• 24 Marzo 2020 - Takis e il Dr Ascierto insieme per combattere il COVID-19

  Da anni, l’istituto Pascale di Napoli è alla frontiera dell’Immunoterapia del Cancro. I ricercatori ed i medici rappresentano non solo l’eccellenza italiana, ma anche mondiale per l’attuazione di strategie terapeutiche…

• 23 March 2020 – Takis on “Il Corriere”: from cancer immunotherapy to Covid-19 vaccine

  Takis is an Italian company, founded by a small group of researchers who never thought of leaving Italy, despite the difficulty in doing good scientific research in this country . This…

• Simone Cristicchi supports Takis research for Covid-19 vaccine!

  The Italian songwriter Simone Cristicchi has made an appeal to support our crowdfunding campaign. We are really grateful to have such a great testimonial helping us to raise money for bringing…

• 21 March 2020 – Takis on the national Chinese TV CGTN

  Our CEO Luigi Aurisicchio has been interviewed on the national Chinese TV CGTN about Takis commitment to develop a Covid-19 genetic vaccine. He described how we designed the vaccine starting from…

• 18 March 2020 – Takis on Italian TV program “Porta a porta” about Covid-19 vaccine

  Our CEO Luigi Aurisicchio has been invited in Skype connection to the Italian TV program “Porta a porta” conducted by Bruno Vespa. He has described our effort to develop a genetic…

• A Crowdfunding initiative to speed up COVID-19 Vaccine development

  Takis scientists are absolutely committed to find solutions to COVID-19 epidemic as soon as possible and are investing time and resources to move forward. However, the next steps up to…

• Rome, 17 March 2020 - Takis, a biotech company in Castel Romano, Rome, announces that it is ready to test…

  Rome, 17 March 2020 - Takis, a biotech company in Castel Romano, Rome, announces that it is ready to test its Covid-19 vaccine on pre-clinical models. The authorization comes from…

• 2 March 2020 - Applied DNA Sciences Updates on COVID-19 Collaboration with Takis Biotech, 4 Preclinical LinearDNA™ Vaccine Candidates Designed

  – Applied DNA Expected to Enter Large-Scale Production of Candidates in March; Preclinical Testing in Animals by Takis Biotech Anticipated to Begin in Calendar Q2 2020 -– Candidates Inspired by…

• 15 February 2020 – Takis is the only Italian company listed in the WHO Covid-19 vaccines roadmap

  A WHO (World Health Organization) meeting took place on 11-12 February to map out companies and academic groups that have announced Covid-19 development programs. Takis is the only Italian company and…

• 15 February 2020 – Watch Takis on the Italian news TGR Officina Italia

  The Italian TV programme TGR Officina Italia has dedicated a television report about Takis and our research activities to develop a vaccine against Covd-19. We announced our commitment as soon…

• 12 February 2020 - TAKIS has applied to European funding initiative to develop a Vaccine and Therapeutics against COVID-19

  12 February 2020 . Takis has applied to the European Call: “Advancing knowledge for the clinical and public health response to the 2019-nCoV epidemic” with the project “EUIMMUnCoV: The European Immunotherapy…

• 9 February 2020 – Takis vaccine against 2019-nCov Coronavirus mentioned on Italian TV channel RAI 3

  Emanuele Marra, Director of infectious diseases area and Fabio Palombo, Director of Immunology and Vaccine area at Takis appeared on the Italian TV programme “Mezz’ora in più” by Lucia Annunziata. They…

• 7 February 2020 – Takis among the “virus hunters” mentioned on Radio 24!

  Takis research has been mentioned on Radio 24 among the worldwide initiatives to characterize and fight Wuhan coronavirus, together with Spallanzani Institute, Campus Biomedico and Rino Rappuoli. Proud to make…

• 7 February 2020 - Takis, LineaRX and Applied DNA Science collaborate for Development of a Linear DNA Vaccine Candidate…

  7 February 2020 - Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”) a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing for product authenticity, traceability solutions, nucleic…

• 29 January 2020 – Takis vaccine against 2019-nCov Coronavirus on La Stampa

  Luigi Aurisicchio, CEO/CSO of Takis and Evvivax, declared in an interview on La Stampa newspaper that our genetic vaccine against 2019-nCov Coronavirus may be ready in about 4 months for…

• Takis and Evvivax developing a 2019-nCoV Coronavirus vaccine

  Rome, 27 January 2020 - Takis and Evvivax, two biotechnology companies present in the science park of Castel Romano, Rome announce their commitment for the development of innovative vaccines against…

• Trazimab as a new promising approach to treat invasive Aspergillosis

  Takis is proud to announce very promising results achieved with Trazimab, a monoclonal antibody against a new target expressed by Aspergillus fumigatus, a fungus which causes Aspergillosis, a rare and…

• 2 December 2019 - Takis second Biotech in Europe at EIT Health Catapult Final!

  Takis second Biotech in Europe at EIT Health Catapult Final! Takis second Biotech in Europe at EIT Health Catapult Final Paris, 2 December, 2019 – NeoMatrix, a neoantigen-based cancer vaccine based on…

• 2-3 December 2019 - PARIS - European EIT Health Biotech Final: Forza Takis and Forza Italia!

  NeoMatrix Personalized Cancer Vaccine Program at EIT Health Final in Paris, 2-3 December 2019 Takis among the 7 European Finalists at EIT Health Summit Paris, 2 December, 2019 – Takis, an Italian…

• Hamburg, Germany – November 13-15 Engage with Takis Biotech at BIO-EUROPE 2019

  TDr Luigi Aurisicchio, CEO/CSO at Takis and Evvivax, will attend Bioeurope 2019. As Europe's largest life science partnering conference, BIO-Europe offers countless opportunities to engage with global life science partners…

• 26 September 2019 - Genomics and personalized medicine. Takis, the Italian excellence in biotechnology, challenges Europe!

  The company of the Tecnopolo di Castel Romano in Rome is among the 7 finalists of the European Health Catapult. The final will be held on 2 and 3 December…

• Trieste – 16-18 October 2019. Takis participating at Meet in Italy for Life Sciences

  Dr Luigi Aurisicchio, CEO/CSO at Takis Biotech has been invited at the workshop “Opportunità per Healthcare Innovative Startup” by the organizers to share its experience as finalist at EIT  Health…

• LineaRx and Takis/Evvivax Anti-Cancer Vaccine Candidates Demonstrate Tumor Reduction

  Tumor Reduction Demonstrated In Vivo Using Two Linear DNA Vaccines in Animal Models STONY BROOK, N.Y., September 19, 2019 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA”), a leader in large-scale PCR-based DNA…

• Expertscape: the research on cancer vaccines of Takis is an excellence in Italy

  The American platform Expertscape has included our CEO and CSO, Dr. Luigi Aurisicchio, in the list of top experts on cancer vaccines in Italy. He ranks  second in the list…

• 1 August 2019 – Takis awarded with the SME Instrument Phase 1

  We are proud to announce that Takis biotech has been awarded with the SME Instrument Phase 1(ot EIC accelerator)  for its program on Neo-Antigen cancer vaccine, TK-Neo. The aim of…

• 18 July 2019 – Takis presents its innovation at “Health Technology and new algorithms for Artificial Intelligence”, Tecnopolo Tiburtino, Rome

  Luigi Aurisicchio, CEO/CSO at Takis, has been invited to the event organized by Tecnopolo S.p.A and dedicated to Health Technology and Artificial Intelligence. The meeting brings togheter companies and academic institutions…

• 4 July 2019 – Takis takes part in the event “Lazio2030: insieme per innovare”

  Our CEO/CSO Luigi Aurisicchio has been invited to the event “Lazio2030: insieme per innovare”, because Takis is among the companies that have successfully used regional support to invest in research…

• 4 June 2019 - Takis semifinalist at the European Health Catapult

  Takis qualified as a semifinalist at the European Health Catapult organized by EIT Health with the support of the Health Axis Europe. This makes  us among the 14 best biotech…

• 3-6 June 2019 – Takis looking for investors at the Bio International Convention of Philadelphia

  Takis has been included in the BOOK “Attrazione per gli investimenti”, distributed at the Bio International Convention of Philadelphia, within the Italy Country Presentation. The Country Presentation is organized by…

• 27 May 2019 - Takis is on Radio Cusano Campus

  Our CEO/CSO Luigi Aurisicchio has been interviewd at Radio Cusano Campus, on the programme “Genetica oggi”. He summarized Takis research in the field of oncology and rare diseases. Our company uses…

• 10 May 2019 – Takis: without research there is no cure

  We are happy to share with you this video shot in our laboratories. This is an overview of our company and wonderful team, made up of experienced and passionate researchers. Our…

• 9 April 2019 - TAKIS announces a collaboration partnership with TRIANNI

  Rome, April 9, 2019 - Takis S.r.l. (“TAKIS”) and Trianni, Inc. ("TRIANNI") today announced Takis access to the Trianni mice platform as service provider. TAKIS is proud to announce that the…

• 11 March 2019 – Takis appears on Il Corriere della Sera newspaper

  This week "Il Corriere della Sera" published an article in the Biotechnology section describing our product Rever3mAb. This is a monoclonal antibody able to “revert” resistance to conventional anticancer therapies. Research…

• 1 March 2019 – Listen about Takis and VITARES on the Radio!

  Luigi Aurisicchio, CEO/CSO at Takis, has been interviewed at Radio Roma Capitale – Live Social. He told the listeners about the story of Takis, Evvivax and VITARES, all born in…

• 5 February 2019 - Takis announces the publication of a paper exploring current antifungal therapeutic strategies

  Takis is proud to announce the publication of the article "The Yin and Yang of Current Antifungal Therapeutic Strategies: How Can We Harness Our Natural Defenses?" by Di Mambro et…

• 27 February – 1 March 2019 – Takis is a sponsor of the 1st VITARES Annual Meeting, Rome, Italy

  Takis is glad to sponsor the first Vitares Annual Congress, which is also the first Italian One Health meeting focusing on Cancer Immunotherapy. This meeting brings together Basic research, Veterinary and…

• 6 February 2019 – Takis publishing data on personalized neoantigen vaccine platform

  We are proud to announce the first POC data achieved in advanced preclinical models with our personalized vaccine platform based on NeoAntigen Identification/DNA Electroporation and published on Journal of Experimental…

• December 2018 - Takis coordinates the project REVER3MAB

  Takis is coordinating the project REVER3MAB, in collaboration with Istituto Regina Elena IRCCS and IBI – Istituto Biochimico Lorenzini, for the development of an anticancer monoclonal antibody aimed at "reverting…

• 4-5 December 2018, Takis and Evvivax at BioFIT, Lille, France

  Dr. Luigi Aurisicchio, CEO/CSO at Takis and Evvivax flew to Lille to represent both the companies at BioFIT 2018. This is the place where academia-industry collaborations get started, an exceptional…

• 14-16 November 2018 – Takis attends NeoAg Summit, Boston

  The NeoAg Summit is the annual industry focused meeting dedicated to advancing neoantigen based cancer vaccines and cell therapies. The meeting brings together research groups and companies from all over…

• 5-7 November - Takis is at BIO-Europe, Copenaghen, Denmark

  Dr. Luigi Aurisicchio, CEO/CSO at Takis and Evvivax, flew to Copenaghen to attend BIO-Europe, the Europe’s largest partnering conference for biotech and life science. Over 4,000 industry attendees from over 60…

• LineaRx signs agreement with Takis/Evvivax to develop linear-DNA based anti-cancer vaccines

  Applied DNA Sciences Inc. ("Applied DNA" or the "Company") announced that LineaRx, Inc. ("LineaRx"), its wholly-owned subsidiary focused on next-generation biotherapeutics, has signed a Joint Development Agreement (the "Agreement") with…

• 11-13 October 2018 – Takis presents at NIBIT (Italian Network for Cancer Biotherapy), Milan, Italy

  In recent decades, there has been a growing development of biological, immunological and pharmacological therapy in the treatment of cancer. NIBIT is the most important network in Italy covering all…

• 10-12 October 2018 – Takis is at Meet in Italy, Bologna, Italy

  Meet in Italy for Life Sciences is the main national meeting of matchmaking and updating in the field of Life Sciences. With the participation of 420 organizations from 37 countries, the…

• 18-21 September 2018 – Takis is a sponsor of the XV Congress of the Italian Federation of Life Sciences (FISV)…

  We are glad to sponsor such an exceptional scientific event for our country, taking place at the Sapienza University of Rome. This is an extraordinary platform where scientists at the…

• March 2018 – Personalized vaccines against cancer, an ambitious program

  Fighting cancer by exploiting the immune system is a very promising field of research. From the earliest stages of tumorigenesis, immune cells function as guardians, prematurely destroying the mutated and…

• 1-3 Feb 2018 - Takis present at 8th meeting on "Advances Against Aspergillosis"

  The Aspergillus field continues in a state of rapid advancement, including the publication of numerous post-genomic papers and substantial advances in translational, immunologic, epidemiologic and diagnostic research.

• New panel for immuno-oncology – available now!

  Takis has recently developed new assays to test in mouse models and in human PBMCs the activity of immune checkpoint inhibitors.

• 30 Nov - Evvivax and ADNAS announce a collaboration to develop DNA-based vaccines

  STONY BROOK, N.Y. (November 30, 2017) — Applied DNA Sciences, Inc. (NASDAQ: APDN) is conducting an evaluation of two animal vaccines with Evvivax srl, an Italian biotech company focused on…

• November 14-16 - Takis presented promising data at NeoAntigen Summit in Boston

  Dr Fabio Palombo - Cancer Vaccine group leader at Takis - presented at Boston:  Developing a neoantigen cancer vaccine strategy by plasmid DNA and electroporation 

• 6-8 November 2017 - Meet Takis at Bio-Europe 2017, Berlin, Germany

  The 23rd annual BIO-Europe is Europe's largest partnering conference serving the global biotechnology industry. Delegates from all parts of the biotechnology value chain come to BIO-Europe to quickly identify,

• 25-29 October - EVVIVAX to present data at the Veterinary Cancer Society, Portland, Oregon (USA)

  Evvivax scientists will be at VCS and present the following abstract: Tel-eVax™:  a Genetic Vaccine targeting Telomerase for treatment of Canine Malignant Lymphoma

• 19 October 2017 - Join us for Prof. Zehn Seminar, Takis/VITARES Education program

  „Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.“ - Someone famous - Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed…

• 5-6 October 2017- Takis presented data at the Italian Forum on Industrial Biotechnology and Bioeconomy in Rome

  Takis was present at IFIB 2017 with two presentations. "We are glad to be part of the Industrial Biotechnology system in Lazio Region. The feedback at IFIB was extremely positive…

• 25-28 September 2017 - Takis and Evvivax at the 2nd World Electroporation Congress

  Takis and Evvivax presented new data at the 2nd World Electroporation Congress in Norfolk, VA. Luigi Aurisicchio showed a wealth of data showing that Electroporation is a great technology for…

• 22 September 2017 - EVVIVAX scientists successfully treat an Asian Elephant with Electrochemotherapy

  EVVIVAX has moved from mice, to cats and dogs and now Elephants! EVVIVAX is proud to be part of the team  treating Juno, a beautiful 50 year old Asian Elephant diagnosed…

• 16 October 2017 - Takis launches a GMP-like DNA Manufacturing Service

  Launching Pre-Clinical Plasmid Manufacturing Professional Quality Plasmids for Pre-Clinical Applications Takis delivers high purity, low endotoxin plasmid preparations suitable for pre-clinical DNA vaccine and gene therapy research in small (mice, rats, rabbits) and…

• 10-13 Sept 2017 - Takis at Antibody Technologies and Therapeutic Conference (Antibody Tech 2017)

  The Antibody Technologies and Therapeutic Conference (Antibody Tech 2017) was held at the Monash University Prato Centre, Italy, from Sunday 10th to Wednesday 13th September 2017. 

• 10-13 Sept 2017 - Takis at Antibody Technologies and Therapeutic Conference (Antibody Tech 2017)

  The Antibody Technologies and Therapeutic Conference (Antibody Tech 2017) was held at the Monash University Prato Centre, Italy, from Sunday 10th to Wednesday 13th September 2017.  This year's meeting brought together internationally recognized…

• 7 July 2017 - VITARES and Takis to host Prof.Luigina Romani for a lecture on the Regulation of anti-infectious immunity…

  We are proud to host Prof. Luigina Romani and are very keen to learn about new discoveries done in her laboratory. Prof. Romani is one of the top scientists in Italy…

• 4 July 2017 - The Newspaper "il Sole 24 Ore" publishes an article on Takis and Biogem Research towards personalized…

  A Personalized Vaccine Against Cancer: this is the ambitious goal of Biogem Research Institute and Takis Biotech. Immuno-oncology  has shown that by unlocking the immune system, extraordinary clinical results that…

• 15 June 2017 - Takis and University Tor Vergata collaborate to find new treatments for Invasive Aspergillosis

  The Aspergillus fungi can cause a variety of diseases, including allergic bronchial pulmonary aspergillosis and invasive aspergillosis. The first occurs in immunocompetent individuals, whereas invasive aspergillosis in immunocompromised patients who…

• 17 May 2017 - Takis hosted at Regione Lazio to show ground-breaking research in Immune-Oncology

  Il 17 maggio 2017 la  Regione Lazio ha ospitato il convegno  “Le nuove sfide della ricerca oncologica: verso una partnership tra Enti Pubblici e Industria nella regione Lazio”, un evento per…

• 10-12 Apr 2017 - Takis and EVVIVAX at the World Vaccine Conference, Washington DC

  Join us at the Annual World Vaccine Congress in Washington DC! The 17th Annual World Vaccine Congress is the place where the global vaccine industry meets to discuss commercial and scientific…

• 1-5 Apr 2017 - Takis to present New Data on Epitope-based Cancer Vaccines at AACR Annual Meeting, Washington DC

  In collaboration with Biogem, Dr Luigi Aurisicchio, CEO/CSO at Takis, will present the Poster: "Epitope-minigenes for optimal induction of the immune response against tumor associated antigens and neoantigens", abstract #5639…

• 31 Mar 2017 - SAVE THE DATE: Takis and VITARES proud to host Prof. Vincenzo Barnaba for a lecture!

  SAVE THE DATE! VITARES and Takis "Formazione" are proud to host Vincenzo Barnaba, Professor of Internal Medicine at the Department of Internal Medicine and Medical Specialties - Sapienza University of Rome and Director…

• 20-24 Mar 2017 - Takis at the Immuno Oncology Summit EUROPE

  Dr Giuseppe Roscilli is joining Immune Oncology Summit Europe, a meeting where Industry and Academic advances in this field merge in cutting-edge science and discussion. Topics: T-cell technology including next-generation CAR Ts, TCRs, and…

• 7 Feb 2017 - Takis proud to host Prof. Andrea Ballabio

  Takis is proud to announce the seminar of Prof. Andrea Ballabio. Prof. Ballabio is: Scientific Director at TIGEM - Naples; Professor of Medical Genetics at the Department of Translational Medicine, University…

• 31 Jan 2017 - Takis supports VITARES Association

  Dr Luigi Aurisicchio, CEO/CSO at Takis and Evvivax, today announced that the Team will support VITARES,  Veterinary Immunotherapy and Translational Research Association: "We are glad to host VITARES in our…

• 2 Jan 2017 - Rever3Mab synergy with Fucoidan as potential treatment for melanoma published on OncoTarget

  Takis team is happy to announce the publication of the paper "The natural compound fucoidan from New Zealand Undaria pinnatifida synergizes with the ERBB inhibitor lapatinib enhancing melanoma growth inhibition…

• 27 Jan 2017 - MULTIPLEXING DONE DIFFERENTLY: flexible, sensitive, and accurate detection of miRNA and protein analytes using Firefly® particle…

  In collaboration with Prodotti Gianni, Takis is happy to announce the presentation of Dr Juan Hidalgo de Quintana, PhD from Abcam. Many multiplex technologies require splitting samples across different wells and…

• 17 Jan 2017 - Relationship between Research and Industry for Vaccine Development. Join us at Dr Valente's seminar!

  In the last twenty years thanks to medicines and vaccines we can cure and prevent fatal diseases. The quality of life has grown and many hopes have become reality for hundreds…

• 5 Dec 2016 - Phages as Vaccine tools: join us at Dr Sartorius' Seminar!

  Phages as valuable tools to be used as a platform for  antigen delivery? Can they activate and sustain a long-lasting adaptive immune response against Cancer and other diseases? Join us to…

• 30 Nov-1 Dec 2016 - Takis to present at Biofit, Lille, France

  Focusing on current issues in Life Sciences, BioFIT 2016’s conference programme promises a varied and rich agenda, featuring the latest opinions on trending topics.Supported by its prestigious Steering Committee, the…

• 7-9 Nov, 2016 - Meet Takis at 22nd Annual International Partnering Conference BIO-EUROPE 2016, Cologne Germany

  Join Takis at Bio-Europe 2016, the Europe's largest partnering conference serving the global biotechnology industry.  Please meet Dr Luigi Aurisicchio, CEO/CSO at ICE Focal Point. Send an email to info@takisbiotech.it to…

• 3 Nov 2016 - Takis announces EVVIVAX, a Company fully dedicated to Pet Cancer Immunotherapy

  Rome, Italy - 3 November 2016: Takis, a Biotechnology Company developing Innovative Genetic Vaccines, Monoclonal Antibodies and platform technologies for Cancer and Infectious diseases, is proud to announce the creation…

• 31 Oct-4 Nov 2016 - Takis presents at the Eight Annual PEGS Europe, Lisbon, Portugal

  PEGS Europe is the largest European event covering all aspects of protein and antibody engineering. Over the last three years, participation at PEGS Europe has grown by more than 60%…

• 26-28 Oct- 2016 - Takis is at Meet in Italy for Life Sciences, Rome, Italy

  Takis has participated at the MIT4LS 2016 edition, an event where Representatives from institutions, companies, clusters and research centers will join together to analyze and discuss strategies, challenges, weakness and…

• 19 Oct 2016 - Interested in antibiotic resistance, microbiome and fungi? Join us at Prof. Sanguinetti's lecture

  Takis' Research is developing immunotherapies against Cancer and pathogens. Moreover, more and more we are learning how microbiome can impact most of physiologic processes in our body. Prof. Sanguinetti is a…

• 28 Sept 2016 - Success for European Biotech Week at Takis

  Takis is delighted to announce that the event "Genetic vaccines: the future for infectious diseases and cancer" was a great success. A number of researchers from different Italian Research Institutions…

• 21 Sept 2016 - Dr Ferrara presented models to predict Lung Cancer chemosensitivity at FISV 2016

  Dr Fabiana F. Ferrara, scientist at Takis Biotech, participated at FISV 2016 (Italian Federation of Life Sciences) with the selected oral presentation:   "Human lung adenocarcinoma cell cultures derived from malignant pleural effusions as model system to predict patients chemosensitivity" outlining the importance of…

• 13 July 2016 - Want to learn more about Tubercolosis and Immune System? Join us at Prof. Delogu Seminar!

  Here the topics that will be discussed by Prof. Delogu: The existing TB vaccine, the attenuated Mycobacterium bovis strain BCG, is effective in protecting infants from severe forms of the disease…

• 8 July 2016 - Takis announces positive results with Rever3mab and Rever3-test

  Takis is proud to announce that Rever3mAb, our lead anti-HER3 antibody, was safe in a regulatory toxicology study conducted in rats. In addition, the antibody pattern of recognition in human tissues…

• 30 June 2016- Education continues! Join us at Dr Salvatori's presentation

  L’aspergillosi invasiva è diventata nell’ultimo ventennio un problema sanitario rilevante in conseguenza dei numerosi trattamenti immunosoppressive in campo oncologico e trapiantologico. La mortalità associata a  questa infezione fungina può arrivare fino…

• 28 September 2016 - Takis labs are open for the Global Biotech Week!

  Takis is proud to announce to be part of the Global Biotech week  in collaboration with Assobiotec. Our scientists will educate visitors showing innovations and driving technologies for cancer therapy…

• 25/28 May 2016 - Takis is at the X SIICA National Conference, Abano Terme (PD)

  Dr Luigi Aurisicchio participated at SIICA, the Italian Society of Immunology, Clinical Immunology and Allergology with two presentations outlining:   1) the importance of canine patients as predictive translational models in Immunology…

• 6 September 2016 - Takis to present at the Comparative Oncology Showcase Day, RVC, London

  Takis' scientists strongly believe that pets represent the best preclinical models in Oncology and Immuno-Oncology. Our results obtained so far in clinical studies performed in Italy and USA strongly support the efficacy…

• 24 May 2016 - Join us at Dr Piaggio's Seminar!

  Dr Giulia Piaggio, Istituto Regina Elena, Rome, will present new data on unique preclinical models that allow Molecular Imaging of Biological Processes during cancerogenesis. The seminar will provide important insights in…

• 10-12 May 2016 - Takis will present new data at the annual CIMT meeting, Mainz, Germany

  Takis is at the frontline of Cancer Immunotherapy with many internal research programs. Dr Luigi Aurisicchio will present at the annual CIMT meeting new data on: "Epitope-minigenes for optimal induction of the immune…

• 29 April 2016 - Join us at Dr Sibilio's seminar!

  Within the "Takis Education" program, Dr Sibilio will provide the state of art for the development of biologics: from discovery in the lab to a real Biotech product. This process requires…

• 21 March 2016 - Dr Luigi Aurisicchio presents Takis' Technology at the Royal Veterinary College, London, UK

  A seminar titled : Harnessing the Immune System to fight Cancer: the power of genetic vectors for Veterinary applications was jointly given by Dr Luigi Aurisicchio (Takis Biotech) and Dr…

• 24 March 2016 - Join us at Dr Piconese's seminar!

  Takis is proud to announce the "Takis Education" program. High level scientists will share their expertise, ideas and discoveries aiming at creating new networks and collaborations. The first seminar will be…

• 2 Dec 2015 - Takis is at BioFit, Strasbourg

  Dr Luigi Aurisicchio has been invited to the following Roud Table: Networks and alliances with the industry: how can TTOs contribute to their success? Industry is increasing its partnering activities…

• 9-11 Nov 2015 - Takis is at the World Veterinary Vaccine Congress, Madrid, Spain

  Takis presents TK-004 at the World Veterinary Vaccines meeting in Madrid.  This event is a great opportunity to meet people involved in Vaccine development, regulatory process, manufacturing and market needs.

• 2-4 Nov 2015 - Takis is at BioEurope, Munich

  Takis is present at BioEurope, a unique event to establish new networks and collaborations with stakeholders, academic centers and big Pharma.

• 15-18 Oct 2015 - Takis presents at the Veterinary Cancer Society, Washington DC

  Dr Luigi Aurisicchio will present compelling data on the increased overall survival in Lymphoma canine patients as a result of combining Chemotherapy with TK004, our Ad/DNA-EGT based cancer vaccine targeting…

• 8-9 Oct 2015 - Takis presents at NIBIT, Siena

  TK-002 stromal vaccine was presented at the "Network Italiano per la Bioterapia dei Tumori" in Siena. Takis attends every year this interesting meeting, where top Italian and International Immunologists meet and…

• 29-30 Sept 2015 - Takis is present at SACHS meeting, Basel, Switzerland

  Takis will attend the 15th Annual Biotech in Europe Forum. The forum is recognised as the leading international stage for those interested in investing and partnering in the biotech and life…

• 16-19 Sept 2015 - Takis presents at CRI-CIMT-EATI-AACR - The Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival

   With the explosion of interest in cancer immunotherapy and the proliferation of scientific meetings in the field, the time is right for a coordinated effort hosted by the field's leaders…

• 14 settembre 2015 - Takis e Biogem sono stati ammessi al finanziamento "Sportello Innovazione" nell'ambito del POR-FESR 2007-2013, Regione…

  Siamo lieti di annunciare che il progetto "Sviluppo di Anticorpi Monoclonali anti-ErbB3 come terapeutici e diagnostici in ambito oncologico", presentato dalla Takis in collaborazione con l'Organismo di Ricerca BIOGEM (www.biogem.it)…

• 1 July 2015 - Open Marketing Position

  Takis Biotech is seeking one Marketing manager. The Research Project is related to finding potential Clients and interest in Anti-ErbB3 antibodies as diagnostic and therapeutic tools in Oncology. The ideal candidate should…

• 18-20 May 2015- Takis presents at MVADS, Leiden

  Takis was selected for an oral presentation on new data on TK004 veterinary cancer vaccine and combination strategy with different immunomodulators at the "Modern Vaccines Adjuvant and Delivery Systems" Conference at Leiden.  

• 22 Apr 2015 - Takis selected to present at BioInItaly Investment Forum

  Dr Luigi Aurisicchio is proud to announce that Takis has been selected for a presentation at the Investor Arena at BioInItaly Investment Forum & Intesa San Paolo Start Up Initiative…

• 18-22 Apr 2015 - Takis presents new data on TK-002 at AACR Annual Meeting in Philadelphia

  "Targeting the Stroma to hit the tumor: MMP11 as a novel target for cancer immunotherapy": this is the title of the poster present by Dr Luigi Aurisicchio at the American…

• January 2015 - Takis awarded with Bando "Promotori Tecnologici per l'innovazione - quarta edizione"

  Takis  announces that the company was selected and awarded by "Città Metropolitana di Roma" to hire a FTE aiming at developing new products. The selection took place among dozen of…

• 20 Dec 2014 - Work with us - Open position for a Immunologist

  In Collaboration with BIOGEM, Takis Biotech is seeking one researcher with expertise in Immunology assays, flow cytometry and cell culture. The Research Project is related to the Development of Anti-ErbB3 antibodies…

• 3-6 November 2014 - Takis presents at BIOEUROPE, Frankfurt

  Takis will attend and present at Biotechnology Partnering Conference - BIO-Europe 2014 in Frankfurt, Germany. For more info: http://www.ebdgroup.com/bioeurope/index.php

• October 2014 - Takis scientists as co-authors in a paper exploiting new combination therapies for invasive pulmonary aspergillosis

  Takis has contributed to a very interesting study conceived by Sigma-Tau collaborators aiming at treating invasive pulmonary aspergillosis (IPA) determined by the fungus Aspergillus Fumigatus. Posaconazole is currently used for the…

• 9-11 October 2014 - Takis presents new data on the cancer vaccine canine clinical trial in the US

  Takis presented new data about the canine clinical trial conducted in collaboration with Dr Impellizeri, Veterinary Oncology Services (VOS), New York, USA (www.petcancerinformation.com/) at the “XIIth NIBIT Meeting- Cancer Bio-Immunotherapy in…

• 29 September 2014 - Takis appears on Sole24 ore Newspaper

  Takis research activities and services have been reported in the 29th September Issue of "Il Sole 24ore", the most important Italian Newspaper about Economy and Finance. Here, the Biotechnology sector…

• 26 September 2014 - Takis progress reported on Sette - Corriere della Sera Newspaper

  Takis announces the publication of an Article by the Corriere della Sera, an important national Newspaper. The article describes Takis as a promising and interesting example of a young Biotech company where…

• 24-26 September 2014 - Takis presents at PIVAC, Rome

  Takis presents new data on "Superior immunologic and therapeutic efficacy of a xenogeneic genetic cancer vaccine targeting human carcinoembryonic antigen" at PIVAC, the 14th international conference on progress in vaccination…

• 17-19 September 2014 - Takis presents at CAVAD, Lausanne

  Luigi Aurisicchio was invited speaker at Cancer Antibodies Vaccines/Adjuvant Delivery, held at CHUV, Lausanne, Switzerland. The titles of the presentations were: "Safety and Efficacyof a Genetic Vaccine targeting Telomerase against…

• 15 September 2014 - Takis' anti-ErbB3 mAbs tested in a novel organoid system at Vanderbilt University

  Takis anti-ErbB3 antibodies were successfuly utilized in a novel system set up at Vanderbilt University. The article "Quantitative optical imaging of primary tumor organoid metabolism predicts drug response in breast…

• 31 August 2014 - Takis co-authors an Oncotarget article describing a novel, aerosol-mediated antibody delivery platform

  Takis is happy to announce the publication of the article "Efficacy of aerosol therapy of lung cancer correlates with EGFR paralysis induced by AvidinOX-anchored biotinylated Cetuximab" appeared on Oncotarget and…

• 24 July 2014 - Takis awarded ISO 9001:2008 certificate

  Takis is proud to announce that the company has been awarded a UNI EN ISO 9001:2008 certificate by Certiquality.  "This is an important achievement for Takis, as it further demonstrate the…

• 15 June 2014 - Work with Us - Position Open for Researchers specialized in Antibody Management

    In partnership with BIOGEM, Takis Biotech is seeking three researchers with strong expertise in Antibody production, characterization and regulatory development. The project where candidates will be involved is on the Development…

• November 2013 - Takis regarded as “Treasures to keep a watch over” on Platinum Magazine

  November 2013 – Takis regarded as “Treasures to keep a watch over” on Platinum Magazine link online page 128  

• 23 November 2013 - Takis Veterinary Cancer Vaccine tested in USA with positive results

  November 23, 2013 FOR IMMEDIATE RELEASE EUROPEAN CANCER VACCINE WITH PROVEN EFFICACY FOR CANINE LYMPHOMA NOW AVAILABLE HERE IN THE UNITED STATES   Canine lymphoma is a devastating disease with survival times ranging from…

• 28 October 2013 -Takis mentioned as promising R&D company in Italy

  On Monday, 28 October 2013 Takis is at page 3 of the Newspaper Il Sole 24 Ore speciale Eventi "Ricerca, Formazione, Innovazione tecnologica".http://websystem.ilsole24ore.com  

• 09 September 2013 - Work with Us - Position Open for a Lab Technician for activities related to generation of…

  In partnership with  academic institutions and other private companies, Takis Biotech has been very recently awarded as partner of the project “MOdelli in Vivo di Patologie UmanE” – MOVIE. For the…